AstraZeneca, University of Pennsylvania School of Medicine form research agreement

By Lisa Kerner

Erie, Pa., March 17 - AstraZeneca plc said it entered into a research collaboration agreement with the University of Pennsylvania School of Medicine for preclinical and clinical research on new treatments for a number of medical conditions.

The renewable, three-year, master agreement establishes a framework for collaboration on a variety of research projects, including addiction, cognition, anxiety, depression and stress-related disorders, according to a company news release.

The specific terms of the agreement were not disclosed.

"There remains a great need for quality research in areas that further our shared goals of bringing innovative medicines safely to patients who need them," AstraZeneca vice president of global medical sciences Rick Sax said in the release.

The University of Pennsylvania School of Medicine has a strong research history in cancer biology, cardiovascular disease, and genetics, among many disciplines, as well as neurology and the neurosciences, according to the release. It is part of the $2.7 billion PENN Medicine enterprise located in Philadelphia.

AstraZeneca researches, develops, manufactures and markets prescription pharmaceuticals and gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. The company is based in London and has U.S. headquarters in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.